Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies DOI Open Access

Styliani Drakoulidou,

Ioannis Ntanasis‐Stathopoulos, Aikaterini Kyritsi

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6461 - 6461

Published: Oct. 28, 2024

Background/Objectives: Monoclonal gammopathies, such as Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), are conditions marked by the overproduction specific monoclonal proteins. Patients with these known to have a higher risk fractures compared general population, yet there no established guidelines for assessing or managing their skeletal health. The Trabecular Bone Score (TBS), which can be calculated from DXA images lumbar spine, provides additional insights into bone microarchitecture. Methods: This study aimed determine whether TBS serve supplementary tool in loss MGUS SMM patients. Conducted 2020 2023, involved 148 participants—74 diagnosed myeloma precursor state 74 healthy controls—who underwent simultaneous measurements. Results: results indicated weak positive correlation (R = 0.405) between T-scores, suggesting that other factors may influence When analyzed separately, correlations remained both 0.250) 0.485). Interestingly, discrepancies were noted T-score classifications; instance, patient classified normal via could deemed osteopenic osteoporotic TBS. Conclusions: Overall, findings suggest incorporating alongside enhance accuracy density assessments, facilitating earlier diagnosis treatment initiation osteoporosis asymptomatic patients gammopathies.

Language: Английский

Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials DOI Creative Commons
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis‐Stathopoulos

et al.

American Journal of Hematology, Journal Year: 2025, Volume and Issue: 100(3), P. 427 - 438

Published: Jan. 9, 2025

This meta-analysis examined the association between minimal residual disease (MRD) negativity and survival outcomes in 15 304 patients with multiple myeloma (MM) enrolled randomized controlled trials published until June 2, 2024. Overall, there was a significant, negative strong MRD odds ratios hazard (β_PFS = -0.20, p < 0.001, β_OS -0.12, 0.023). These associations remained significant for newly diagnosed -0.35, 0.001), they were consistent but not relapsed/refractory -0.06, 0.635). Sustained at 1 year strongly correlated prolonged PFS -0.30, 0.001). In conclusion, this comprehensive supports as surrogate MM.

Language: Английский

Citations

3
Current Treatment Strategies for Multiple Myeloma at First Relapse DOI Open Access
Evangelos Mavrothalassitis,

Konstantinos Triantafyllakis,

Panagiotis Malandrakis

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1655 - 1655

Published: Feb. 28, 2025

Multiple myeloma (MM), the second most common hematologic cancer, remains an incurable malignancy, characterized by initial response to therapy followed successive relapses. The upfront treatment typically involves induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance therapy. It is important note that anticipated duration of diminishes with each subsequent relapse. Therefore, first relapse represents a critical juncture in treatment, where refractoriness key drug classes emerges as significant challenge. Addressing optimal management this setting requires careful consideration disease biology, prior therapies, patient-specific factors optimize outcomes. Cilta-cel, chimeric antigen receptor T-cell construct, has emerged promising therapeutic option at relapse, resulting remissions treatment-free interval. However, availability accessibility are not universal logistics complex. Triplet regimens based on carfilzomib, pomalidomide or selinexor, remain cornerstone whereas combination drugs, especially anti-CD38 monoclonal antibodies lenalidomide, patient comorbidities. With rapidly expanding landscape, clinicians face increasing complexity selecting appropriate individual patients. This review aims guide through these evolving options consolidating evidence-based strategies highlighting emerging ensuring personalized approach managing first-relapse MM.

Language: Английский

Citations

0
Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China DOI Creative Commons
Xiaoyan Han,

Xincheng Jiang,

Jingsong He

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(9)

Published: May 1, 2024

Abstract Background Comparative investigations evaluating the efficacy of pomalidomide‐based (Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with relapsed/refractory multiple myeloma (RRMM) remain scarce, both randomized controlled trials and real‐world studies. Methods This retrospective cohort study included 140 RRMM treated Pom‐based or Dara‐based a combination pomalidomide daratumumab (DPd) regimens Chinese tertiary hospital between December 2018 July 2023. Results The overall response rates (ORR) for ( n = 48), 68), DPd 24) groups were 57.8%, 84.6%, 75.0%, respectively p 0.007). At data cutoff on August 1, 2023, median progression‐free survival (PFS) was 5.7 months (95% CI: 5.0–6.5) group, 10.5 (5.2–15.8) 6.7 (4.0–9.3) group 0.056). Multivariate analysis identified treatment (Dara‐based vs. Pom‐based, Pom‐based) Eastern Cooperative Oncology Group performance status (ECOG PS) as independent prognostic factors PFS. In subgroups aged >65 years, ECOG PS ≥2, lines therapy extramedullary disease double‐refractory (refractory to lenalidomide proteasome inhibitors), superiority over not evident. A higher incidence infections observed receiving (Pom‐based 39.6% 64.7% 70.8%, 0.009). Conclusions settings, Dara‐based, exhibited favorable RRMM. yielded superior clinical PFS compared therapy.

Language: Английский

Citations

2
The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients DOI Creative Commons
Linlin Huang, Yi Zhong, Qingxiao Chen

et al.

Cancer Biology & Therapy, Journal Year: 2024, Volume and Issue: 25(1)

Published: Sept. 18, 2024

Objective Myeloma-related bone disease (MBD) is one of the most common complications multiple myeloma (MM). This study aims to investigate correlation between serum metabolism indexes (BMIs), clinical characteristics and prognosis newly diagnosed MM (NDMM) patients.

Language: Английский

Citations

0
Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies DOI Open Access

Styliani Drakoulidou,

Ioannis Ntanasis‐Stathopoulos, Aikaterini Kyritsi

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6461 - 6461

Published: Oct. 28, 2024

Background/Objectives: Monoclonal gammopathies, such as Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), are conditions marked by the overproduction specific monoclonal proteins. Patients with these known to have a higher risk fractures compared general population, yet there no established guidelines for assessing or managing their skeletal health. The Trabecular Bone Score (TBS), which can be calculated from DXA images lumbar spine, provides additional insights into bone microarchitecture. Methods: This study aimed determine whether TBS serve supplementary tool in loss MGUS SMM patients. Conducted 2020 2023, involved 148 participants—74 diagnosed myeloma precursor state 74 healthy controls—who underwent simultaneous measurements. Results: results indicated weak positive correlation (R = 0.405) between T-scores, suggesting that other factors may influence When analyzed separately, correlations remained both 0.250) 0.485). Interestingly, discrepancies were noted T-score classifications; instance, patient classified normal via could deemed osteopenic osteoporotic TBS. Conclusions: Overall, findings suggest incorporating alongside enhance accuracy density assessments, facilitating earlier diagnosis treatment initiation osteoporosis asymptomatic patients gammopathies.

Language: Английский

Citations

0